Company news

Coherus Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

August 3, 2022

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

August 1, 2022

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

July 27, 2022

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

July 5, 2022

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

May 10, 2022

Coherus BioSciences Reports First Quarter 2022 Results

May 4, 2022

Coherus BioSciences Appoints Charlie Newton to Board of Directors

May 4, 2022

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

April 28, 2022

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States

April 13, 2022

Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer

March 14, 2022

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

February 16, 2022

Coherus Names Paul Reider Chief Commercial Officer

February 14, 2022

Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors

February 6, 2022

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

January 9, 2022

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

January 6, 2022

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

December 19, 2021

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

December 16, 2021

Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

November 14, 2021

Coherus BioSciences Reports Third Quarter 2021 Results

November 7, 2021

Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

November 4, 2021

Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma

October 31, 2021

Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th

October 28, 2021

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

October 10, 2021

Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial

October 4, 2021

Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review

September 30, 2021

Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal...

September 15, 2021

Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine

September 14, 2021

Coherus BioSciences Announces Upcoming Medical Conference Presentations

September 7, 2021

Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

August 31, 2021

Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

August 17, 2021

Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

August 4, 2021

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

July 20, 2021

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

June 3, 2021

Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

May 5, 2021

Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

April 29, 2021

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

April 22, 2021

Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences

April 19, 2021

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma

March 2, 2021

Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021

Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

February 16, 2021

Coherus Announces CFO Transition Plans

February 15, 2021

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

February 1, 2021

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada

January 31, 2021

Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors

January 6, 2021

Coherus BioSciences Reports Third Quarter 2020 Financial Results

November 4, 2020

Coherus BioSciences to Report Third Quarter Financial Results on November 5th

October 21, 2020

Coherus BioSciences Reports Second Quarter 2020 Financial Results

August 5, 2020

Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors

August 2, 2020

Coherus BioSciences to Report Second Quarter Financial Results on August 6th

July 15, 2020

Coherus BioSciences Reports First Quarter 2020 Financial Results

May 6, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks